RxDoctor Payments Data

Robert Arleo, MD

Ophthalmology · Ithaca, NYNPI 1952416216

Payments from drug & device makers

$28,573in general payments, 2019–2025

Across 39 payments — averaging $732.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$17K
  • AbbVie$10K
  • Alcon$1K
  • Glaukos Corporation$97
  • Ivantis, Inc$16

What the payments were for

  • Speaking & faculty fees$7,95070%
  • Travel & lodging$1,83916%
  • Food & beverage$1,59914%
  • Education$400%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon Research LLC3$17,145
AbbVie(2 entities)12$10,205
Alcon22$1,110
Glaukos Corporation1$97
Ivantis, Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,573 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$263,687
Medicare patients
650
Services billed
1,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Travoprost86$19,457
Timolol Maleate217$17,101
LumiganBimatoprost25$16,660
Prednisolone Acetate266$11,643
SimbrinzaBrinzolamide/Brimonidine Tart30$11,311
Ketorolac Tromethamine219$5,549
Brimonidine Tartrate66$2,588
Brinzolamide11$2,561
Ciprofloxacin Hcl195$2,051
Latanoprost163$1,883
Dorzolamide Hcl56$936
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$437
ErythromycinErythromycin Base17$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$10,205$16,66025 claims
AlconSimbrinza$1,110$11,31130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →